The overall objective of this proposal is to establish clinical research sites for three HIV/AIDS Clinical Trials Networks: Vaccine Research and Development, HIV Prevention, and Optimization of Clinical Management, including Co-morbidities.
The specific aims of the NCAIDS CTU are as follows: (1) To conduct clinical trials assessing the safety, immunogenicity, and efficacy of selected candidate HIV-1 vaccines in high-risk populations;(2)To conduct clinical trials evaluating the efficacy and acceptability of promising behavioral and biomedical intervention strategies for preventing HIV transmission in high risk populations;(3)To conduct clinical trials evaluating new therapies against HIV-infection or co-infections with the goal of optimizing the therapeutic effects, increasing medication adherence, elucidating novel mechanisms, and improving features in resistance and toxicological properties;(4)To ensure the clinical trial capability in China adheres to international standards and good clinical practices in order to evaluate strategies for prevention, intervention, and treatment of HIV infection;(5)To further develop the clinical trial infrastructure and enhance the expertise and skills of Chinese investigators, students, and staff to strengthen the HIV prevention and control efforts in China. The main population for the vaccine and prevention research will be intravenous;drug users living in Urumqi City in Xinjiang Autonomous Region, Longchuan County in Yunnan Province, and Shizhong District of Leshan City in Sichuan Province. Research for the optimization of clinical management will be conducted at Beijing Ditan Hospital, Beijing Youan Hospital, and Guangzhou Number 8 People's Hospital in Guangdong Province. These six proposed sites are qualified for implementing clinical trial protocols and have the capacity to enroll sufficient numbers of study subjects. By adhering to good clinical practices, standard operating procedures, and the study protocols, and conducting quality assurance and control measures, the clinical research in the proposed sites will be implemented well and will meet international standards. The HIV epidemic in China has begun to spread from high risk groups to the general population. China urgently needs to join international research aiming at finding new prevention and treatment methods against HIV. Successful implementation of clinical trials on HIV vaccine, behavioral and biomedical prevention, and treatment will greatly assist efforts to control and prevent HIV/AIDS in China and the rest of the world. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
4UM1AI069411-07
Application #
8415778
Study Section
Special Emphasis Panel (ZAI1-SR-A (M3))
Program Officer
Roth, Lynnea L
Project Start
2007-07-01
Project End
2014-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
7
Fiscal Year
2013
Total Cost
$1
Indirect Cost
$19,316
Name
National Center/AIDS/Std Control/Prevent
Department
Type
DUNS #
545274532
City
Beijing
State
Country
China
Zip Code
10220-6
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905